Presiding over the upward trajectory of Eli Lilly over the last eight years is paying off nicely for CEO David Ricks. | ...

Eli Lilly (LLY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Parnassus Investments, an investment management company, released the “Parnassus Core Equity Fund” fourth quarter 2024 ...

Lilly looks poised to hit a $1 trillion market value Shares of Eli Lilly haven't been doing well in recent months, but over the long run, I think they will more than recover. This is a company ...

Warning! GuruFocus has detected 6 Warning Signs with ORCL. As of 2025-02-25, Eli Lilly and Co's intrinsic value as calculated by the Discounted Earnings model is $271.69. It's currently trading at ...

The bottom line: We're raising our Lilly fair value estimate to $620 from $580 to account for higher long-term growth from the oncology and immunology portfolio, which supports the firm's wide ...

The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Eli Lilly, situated within the strike price corridor from $380.0 to ...

Lilly's key products include Verzenio for cancer ... reaching $823.41. Current RSI values indicate that the stock is may be approaching oversold. Next earnings report is scheduled for 51 days ...